Welcome to our dedicated page for azrx news (Ticker: azrx), a resource for investors and traders seeking the latest updates and insights on azrx stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect azrx's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of azrx's position in the market.
AzurRx BioPharma has appointed Terry Coelho to its Board of Directors, expanding the board to seven members. Coelho, who has over 30 years of financial and operational experience, is currently the CFO at BioDelivery Sciences.
Her appointment is expected to enhance AzurRx's growth strategy, particularly in developing therapies for gastrointestinal diseases. Coelho aims to leverage her background in the pharmaceutical industry to aid in achieving the company’s goals and benefiting shareholders.
AzurRx BioPharma (NASDAQ: AZRX) announced the completion of enrollment for Part 1 of its Phase 2 RESERVOIR clinical trial assessing FW-1022, an oral formulation of niclosamide for treating COVID-19-related gastrointestinal infections. With approximately 20% of COVID-19 patients experiencing GI symptoms, the trial aims to evaluate FW-1022's safety and efficacy in clearing the SARS-CoV-2 virus from the GI tract. Results from the first cohort will be reviewed by the Data Monitoring Committee before proceeding to Part 2, which focuses on efficacy. Topline results are expected in Q1 2022.
AzurRx BioPharma has expanded its RESERVOIR Phase 2 clinical trial for FW-1022, targeting COVID-19-related gastrointestinal infections, by adding five new sites in Ukraine. The study aims to evaluate the safety and efficacy of FW-1022, a micronized niclosamide formulation, in clearing SARS-CoV-2 from the GI tract. With COVID-19 symptoms reported in 18% of cases, the trial could provide insights into potential treatments for long-term effects of COVID. Topline data is expected in Q1 2022. The increasing vaccination gap in Ukraine strengthens the trial's patient recruitment potential.
AzurRx BioPharma, Inc. (NASDAQ: AZRX) announced the closing of its underwritten public offering of 10,454,546 shares at $0.55 per share, including an additional 1,363,636 shares from the underwriter's option. The gross proceeds total approximately $5.75 million, aimed primarily for milestone payments under license agreements and general corporate purposes, such as product manufacturing and clinical development. The offering was conducted under an effective shelf registration statement with the SEC.
AzurRx BioPharma, Inc. (NASDAQ: AZRX) announced an increase in its public offering, with the underwriter set to purchase 9,090,910 shares at $0.55 each, expected to close by July 27, 2021. Gross proceeds are projected at approximately $5.0 million. The funds will support milestone payments under license agreements and general corporate purposes, including product manufacturing and clinical development. The offering is part of a previously filed shelf registration statement with the SEC, and the underwriter has a 30-day option for an additional 1,363,636 shares.
AzurRx BioPharma (NASDAQ: AZRX) has entered an underwriting agreement with H.C. Wainwright & Co. for the sale of 5,454,546 shares at $0.55 each, aiming to raise approximately $3.0 million in gross proceeds. The offering is set to close around July 27, 2021, subject to customary conditions. The funds will primarily support milestone payments under license agreements and general corporate purposes, including product manufacturing and clinical development. The shares are offered under an existing shelf registration statement with the SEC.
AzurRx BioPharma, a clinical stage biopharmaceutical company focused on gastrointestinal diseases, announced the participation of CEO James Sapirstein at the 2021 BIO Digital conference on June 10-11 and June 14-18. He will present an overview of the company’s business and pipeline, including anticipated milestones for 2021 and early 2022. The presentation will be available on demand starting June 10, 2021. Additionally, management will engage in one-on-one meetings with registered investors and pharmaceutical executives.
AzurRx BioPharma (NASDAQ: AZRX) announced the first dose administration of FW-1022 in the Phase 2 RESERVOIR clinical trial targeting COVID-19-related gastrointestinal (GI) infections. With topline results expected in Q1 2022, the trial aims to confirm safety and evaluate efficacy in clearing SARS-CoV-2 from the GI tract. Approximately 18% of COVID-19 cases report GI symptoms, creating a demand for targeted treatments. FW-1022, a micronized niclosamide tablet, could potentially treat severe GI complications and aims to improve long-term COVID-19 symptoms.
AzurRx BioPharma (NASDAQ: AZRX) announced James Sapirstein, President and CEO, will present at the Rocky Mountain Microcap Conference on May 26, 2021, at 12:28 p.m. EDT. During his presentation, he will discuss the company’s business, clinical development programs, and upcoming milestones for 2021 and early 2022. Attendees can also schedule one-on-one meetings with management. AzurRx specializes in developing targeted therapies for gastrointestinal diseases, including its lead candidate, MS1819, which is in Phase 2 trials.
AzurRx BioPharma (NASDAQ: AZRX) announced positive interim results from its Phase 2 trial evaluating MS1819 in combination with porcine-derived pancreatic enzyme replacement therapy (PERT) for treating severe exocrine pancreatic insufficiency (EPI) in cystic fibrosis (CF) patients. The first 18 patients showed a significant average improvement of 5.9 points in the Coefficient of Fat Absorption (CFA), exceeding the clinically significant threshold. Full results from 20 patients are expected in Q2 2021, with potential implications for patients unable to achieve adequate nutrition using PERT alone.
